$ALLO insider trading
Over the last 12 months, Allogene Therapeutics insiders reported no purchases and 15 sales totaling $666K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $666K 15 events
- Events · 12m
- 15 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Douglas Earl MartinSVP, General Counsel · O | ▼ Sale | 29,697 | $2.12 | $63K | -5.7% | — |
| Apr 21, 2026 | Yoshiyama AnnieSVP, Finance · O | ▼ Sale | 9,586 | $2.31 | $22K | -7.1% | — |
| Mar 31, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer · O | ▼ Sale | 2,867 | $2.5 | $7K | -1.4% | — |
| Mar 16, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer · O | ▼ Sale | 4,835 | $2.47 | $12K | -2.4% | — |
| Mar 16, 2026 | Chang David DPresident and CEO · O·D | ▼ Sale | 47,763 | $2.47 | $118K | -0.9% | — |
| Mar 2, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer · O | ▼ Sale | 7,132 | $2.6 | $19K | -3.4% | — |
| Feb 2, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer · O | ▼ Sale | 7,549 | $1.73 | $13K | -3.5% | — |
| Feb 2, 2026 | Chang David DPresident and CEO · O·D | ▼ Sale | 95,269 | $1.8 | $171K | -1.8% | — |
| Feb 2, 2026 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 24,001 | $1.76 | $42K | -1.9% | — |
| Feb 2, 2026 | Yoshiyama AnnieSVP, Finance · O | ▼ Sale | 4,167 | $1.72 | $7K | -3.1% | — |
| Feb 2, 2026 | Roberts ZacharyEVP of R&D · O | ▼ Sale | 35,700 | $1.77 | $63K | -5.8% | — |
| Feb 2, 2026 | Douglas Earl MartinSVP, General Counsel · O | ▼ Sale | 22,900 | $1.76 | $40K | -3.9% | — |
| Jan 21, 2026 | Roberts ZacharyEVP of R&D · O | ▼ Sale | 26,269 | $1.56 | $41K | -4.1% | — |
| Nov 17, 2025 | Beneski Benjamin MachinasSVP, Chief Technical Officer · O | ▼ Sale | 786 | $1.22 | $959 | -0.4% | — |
| Oct 21, 2025 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 36,744 | $1.26 | $46K | -2.8% | — |
Every $ALLO filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Allogene Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ALLO feed.